Rezo Therapeutics identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence.
Rezo Therapeutics identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence. Rezo's proprietary platform can be used to treat a wide range of diseases. Rezo's initial focus is oncology, with plans to expand into other therapeutic areas through collaborations and partnerships.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 17, 2022 | Series A | $78M | 9 | Norwest Venture Partners Andreessen Horowitz SR One | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Norwest Venture Partners | Yes | Series A |
Andreessen Horowitz | Yes | Series A |
SR One | Yes | Series A |
Alexandria Venture Investments | — | Series A |
Eli Lilly | — | Series A |
Hawktail Management | — | Series A |
Liquid 2 Ventures | — | Series A |
SVA | — | Series A |
UCSF Foundation Investment Company | — | Series A |